Implementing the policy of import substitution in endocrinology, JSC Pharmasyntez took part in the Forum as a leading sponsor. For the first time at the Congress this size, a Russian company introduced a broad range of generic drugs, the most in-demand oral antihyperglycemic drugs for type 2 diabetes. All the drugs range aroused great interest both of the specialists and the Congress participants. 
Pharmasyntez Group is the most important manufacturer of socially significant drugs in Russia. It has more than 20 years success. Production of drugs for type 2 diabetes mellitus is an integral part of the company’s strategic development plan.
The introduced drugs will be manufactured at the Tyumen plant as per international quality standards. They are in great demand in the pharmaceutical market and can increase the level of access to domestic innovative endocrine drugs. 
The All-Russian Diabetes Congress is a unique platform for endocrinologists to get informed about most advanced treatment methods and to discuss new promising scientific projects focused on fundamental research or implementation of multidisciplinary treatment paradigm for diabetic patients and of diabetes complications.